NO20044850L - Nye antagonister for MCP proteiner - Google Patents

Nye antagonister for MCP proteiner

Info

Publication number
NO20044850L
NO20044850L NO20044850A NO20044850A NO20044850L NO 20044850 L NO20044850 L NO 20044850L NO 20044850 A NO20044850 A NO 20044850A NO 20044850 A NO20044850 A NO 20044850A NO 20044850 L NO20044850 L NO 20044850L
Authority
NO
Norway
Prior art keywords
mcp
proteins
mcp proteins
diseases
novel antagonists
Prior art date
Application number
NO20044850A
Other languages
English (en)
Inventor
Amanda Proudfoot
Marie Kosco-Vilbois
Tracy Handel
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of NO20044850L publication Critical patent/NO20044850L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SAMMENDRAG Nye antagonister av MCP-proteiner, da spesielt MCP-1-protein, kan oppnås ved å utvikle MCP-mutanter hvis GAG-bindende sete som er plassert i N-terminalen av MCP-proteinene, blir eliminert ved hjelp av ikke-konservative substitusjoner. Forbindelser fremstilt ifølge den foreliggende oppfinnelsen kan brukes for å behandle eller å hindre sykdommer som er relatert til en uønsket aktivitet av MCP-proteiner så som inflammatoriske sykdommer, autoimmune sykdommer, vaskulære sykdommer og kreft.
NO20044850A 2002-04-10 2004-11-08 Nye antagonister for MCP proteiner NO20044850L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37144202P 2002-04-10 2002-04-10
PCT/EP2003/050097 WO2003084993A1 (en) 2002-04-10 2003-04-09 Novel antagonists of mcp proteins

Publications (1)

Publication Number Publication Date
NO20044850L true NO20044850L (no) 2004-12-09

Family

ID=28792054

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044850A NO20044850L (no) 2002-04-10 2004-11-08 Nye antagonister for MCP proteiner

Country Status (18)

Country Link
US (1) US7425324B2 (no)
EP (1) EP1495050A1 (no)
JP (1) JP2006505243A (no)
KR (1) KR20040101426A (no)
CN (1) CN1665839A (no)
AR (1) AR039629A1 (no)
AU (1) AU2003240765A1 (no)
BR (1) BR0309238A (no)
CA (1) CA2509767A1 (no)
EA (1) EA200401342A1 (no)
HR (1) HRP20040946A2 (no)
IL (1) IL164464A0 (no)
MX (1) MXPA04009874A (no)
NO (1) NO20044850L (no)
PL (1) PL373007A1 (no)
RS (1) RS89104A (no)
WO (1) WO2003084993A1 (no)
ZA (1) ZA200409062B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR046594A1 (es) * 2003-10-16 2005-12-14 Applied Research Systems Usos terapeuticos de variantes de quemoquina
US20050232923A1 (en) * 2003-11-05 2005-10-20 Li Yan Methods and compositions for treating MCP-1 related pathologies
US20050106740A1 (en) * 2003-11-13 2005-05-19 Boyes Barry E. Methods, systems and devices for performing analytical protocols
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
GB0412400D0 (en) * 2004-06-03 2004-07-07 Univ Newcastle Treatment of inflammatory conditions
CA2618951A1 (en) 2005-08-12 2007-02-22 Schering Corporation Mcp1 fusions
EP2041568A4 (en) * 2006-06-15 2009-08-12 CCR2 ANTAGONISTS FOR CHRONIC BREATHING REACTIONS IN ORGAN TRANSPLANTATIONS
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
US10745701B2 (en) 2007-06-28 2020-08-18 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
US20090324596A1 (en) 2008-06-30 2009-12-31 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
EP2042516A1 (en) 2007-09-27 2009-04-01 Protaffin Biotechnologie AG Glycosaminoglycan-antagonising MCP-1 mutants and methods of using same
EP2391645A1 (en) 2009-01-30 2011-12-07 Protaffin Biotechnologie AG Glycosaminoglycan-antagonising mcp-i mutants and methods of using same
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
KR101238196B1 (ko) * 2010-12-16 2013-02-28 사회복지법인 삼성생명공익재단 대장암의 간 전이 진단용 조성물 및 그 용도
US20180206726A1 (en) 2016-12-07 2018-07-26 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112264A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5094941A (en) * 1987-12-31 1992-03-10 Zymogenetics, Inc. Monoclonal antibodies to PDGF
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins

Also Published As

Publication number Publication date
AU2003240765A1 (en) 2003-10-20
CN1665839A (zh) 2005-09-07
BR0309238A (pt) 2005-02-15
US20070004906A1 (en) 2007-01-04
ZA200409062B (en) 2005-11-09
HRP20040946A2 (en) 2005-06-30
WO2003084993A1 (en) 2003-10-16
MXPA04009874A (es) 2005-10-19
EP1495050A1 (en) 2005-01-12
JP2006505243A (ja) 2006-02-16
EA200401342A1 (ru) 2005-08-25
US7425324B2 (en) 2008-09-16
AR039629A1 (es) 2005-03-02
KR20040101426A (ko) 2004-12-02
PL373007A1 (en) 2005-08-08
CA2509767A1 (en) 2003-10-16
IL164464A0 (en) 2005-12-18
RS89104A (en) 2006-12-15

Similar Documents

Publication Publication Date Title
NO20044850L (no) Nye antagonister for MCP proteiner
Wolk et al. IL‐22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis
EA200400586A1 (ru) Замещённые тиоацетамиды
ATE394400T1 (de) Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
ATE556060T1 (de) Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
ATE229515T1 (de) (methylsulfonyl)phenyl-2-(5h)-furanone als cox-2 inhibitoren
EA200500856A1 (ru) Новые химические соединения
NO20060319L (no) 3,5-disubstituerte indazolforbindelser, farmasoytiske blandinger og fremgangsmater for a mediere eller inhibere celleproliferasjon
EA199900021A1 (ru) Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
Amat et al. Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo
Harwig et al. Determination of disulphide bridges in PG‐2, an antimicrobial peptide from porcine leukocytes
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
MA31899B1 (fr) Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
ATE250577T1 (de) Indolderivate und ihre verwendung als mcp-1 rezeptor antagonisten
NO20062630L (no) TP-10 Antistoffer og deres anvendelse
DE60236536D1 (de) Modifizierter anti-tnf antikörper
ATE321855T1 (de) Tumor-nekrose-faktor rezeptor 5
EA200501506A1 (ru) Антитела против il-20 и связывающие партнеры, а также способы их применения при воспалении
ATE444960T1 (de) Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer
DE602005027258D1 (de) Humane monoklonale antikörper gegen hendra- und nipah-viren
CY1106799T1 (el) Ανταγωνιστες των cxcr3-συνδεσης cxc χημειοκινων
DE60214990D1 (de) Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

FC2A Withdrawal, rejection or dismissal of laid open patent application